HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?

Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1510
https://www.valueinhealthjournal.com/article/S1098-3015(23)04640-5/fulltext
Title : HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04640-5&doi=10.1016/j.jval.2023.09.1510
First page :
Section Title :
Open access? : No
Section Order : 10959
Categories :
Tags :
Regions :
ViH Article Tags :